Last updated on March 2007

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Myelodysplastic Syndromes
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    Age > 18 years at the time of signing the informed consent form
    MDS with IPSS scores Int-2 or high with deletion 5q(31)
    Prior thalidomide allowed
    Documented diagnosis of MDS (RA, RARS, RAEB, RAEB-T and CMML with WBC < 13,000/mm3
    according to FAB classification) that meets IPSS criteria for intermediate-2 or
    high-risk disease and has an associated del 5q[31] (the deleted chromosomal region
    must include 5q[31]), with or without additional cytogenetic abnormalities

You may not be eligible for this study if the following are true:

  • Pregnant or lactating females
    Prior therapy with lenalidomide
    MDS with IPSS scores low or Int-1
    Clinical neuropathy of greater than grade 2
    Proliferative (WBC ≥ 13,000/mL) chronic myelomonocytic leukemia (CMML)
    Recombinant human erythropoietin (rHuEPO) therapy received within 28 days
    Use of androgens other than for treating hypogonadism

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.